The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding
Open accessAbstract
A major challenge for the therapeutic use of many peptides and proteins is their short circulatory half-life. Albumin has an extended serum half-life of 3 weeks because of its size and FcRn-mediated recycling that prevents intracellular degradation, properties shared with IgG antibodies. Engineering the strictly pH-dependent IgG-FcRn interaction is known to extend IgG half-life. However, this principle has not been extensively explored for albumin. We have engineered human albumin by introducing single point mutations in the C-terminal end that generated a panel of variants with greatly improved affinities for FcRn. One variant (K573P) with 12-fold improved affinity showed extended serum half-life in normal mice, mice transgenic for human FcRn, and cynomolgus monkeys. Importantly, favorable binding to FcRn was maintained when a single-chain fragment variable antibody was genetically fused to either the N- or the C-terminal end. The engineered albumin variants may be attractive for improving the serum half-life of biopharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This occurs at a lower rate in health.22”
From Hypoalbuminemia: Pathogenesis and Clinical Significance (2019) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure of human serum albumin at 2.5 Å resolution
Sugio, S., Kashima, A., Mochizuki, S., Noda, M., & Kobayashi, K. (1999) · Protein Engineering Design and Selection · doi:10.1093/protein/12.6.439 · Cited by 1,816
Curry, S., Mandelkow, H., Brick, P., & Franks, N. P. (1998) · Nature Structural Biology · doi:10.1038/1869 · Cited by 1,378
Quantitative analysis of protein far UV circular dichroism spectra by neural networks
Böhm, G., Muhr, R., & Jaenicke, R. (1992) · Protein Engineering Design and Selection · doi:10.1093/protein/5.3.191 · Cited by 1,114
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 853
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature reviews. Immunology · doi:10.1038/nri2761 · Cited by 846
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 667
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640
Albumin as a versatile platform for drug half-life extension
Sleep, D., Cameron, J., & Evans, L. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.023 · Cited by 510
Self-citationCrystal structural analysis of human serum albumin complexed with hemin and fatty acid
Zunszain, P. A., Ghuman, J., Komatsu, T., Tsuchida, E., & Curry, S. (2003) · BMC Structural Biology · doi:10.1186/1472-6807-3-6 · Cited by 509
Ober, R. J., Radu, C. G., Ghetie, V. F., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 502
Flagged first, then by citations
Cited by
Sorted by citations
Hypoalbuminemia: Pathogenesis and Clinical Significance
Soeters, P. B., Wolfe, R. R., & Shenkin, A. (2019) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1451 · Cited by 1,448
Albumin-based drug delivery: harnessing nature to cure disease
Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 704
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
Strohl, W. R. (2015) · BioDrugs · doi:10.1007/s40259-015-0133-6 · Cited by 479
Albumin and its application in drug delivery
Sleep, D. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.993313 · Cited by 470
Self-citationThe Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 450
Self-citationBiomacromolecules as carriers in drug delivery and tissue engineering
Zhang, Y., Sun, T., & Jiang, C. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.11.005 · Cited by 424
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Self-citationDevelopability Assessment During the Selection of Novel Therapeutic Antibodies
Jarasch, A., Koll, H., Regula, J. T., Bader, M., Papadimitriou, A., & Kettenberger, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24430 · Cited by 242
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
Sockolosky, J. T., & Szoka, F. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.005 · Cited by 253
Synthetic fusion protein design and applications
Yu, K., Liu, C., Kim, B., & Lee, D. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.11.005 · Cited by 241
The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery
Bern, M., Sand, K. M. K., Nilsen, J., Sandlie, I., & Andersen, J. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.006 · Cited by 224
Self-citationHalf-life extended biotherapeutics
Kontermann, R. E. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1165661 · Cited by 197
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment
Kintzing, J. R., Interrante, M. V. F., & Cochran, J. R. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.005 · Cited by 199
Bernardim, B., Cal, P. M. S. D., Matos, M. J., Oliveira, B. L., Martínez‐Sáez, N., Albuquerque, I. S., Perkins, E., Corzana, F., Burtoloso, A. C. B., Jiménez‐Osés, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms13128 · Cited by 188
Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation
van Witteloostuijn, S. B., Pedersen, S. L., & Jensen, K. J. (2016) · ChemMedChem · doi:10.1002/cmdc.201600374 · Cited by 194
A review of lipidation in the development of advanced protein and peptide therapeutics
Menacho‐Melgar, R., Decker, J. S., Hennigan, J. N., & Lynch, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.032 · Cited by 159
Derivatization with fatty acids in peptide and protein drug discovery
Kurtzhals, P., Østergaard, S., Nishimura, E., & Kjeldsen, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00529-w · Cited by 139
Serum albumin: clinical significance of drug binding and development as drug delivery vehicle
Tayyab, S., & Feroz, S. R. (2020) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2020.08.003 · Cited by 119
Lombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 130
Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides
Datta‐Mannan, A. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086488 · Cited by 113
Targeting FcRn to Generate Antibody-Based Therapeutics
Ward, E. S., & Ober, R. J. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.007 · Cited by 112
AlQahtani, A. D., O’Connor, D., Dömling, A. S. S., & Goda, S. K. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108750 · Cited by 109
Komara, N., Paragomi, P., Greer, P. J., Wilson, A. S., Breze, C. R., Papachristou, G. I., & Whitcomb, D. C. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00285.2020 · Cited by 106
Chemoselective Installation of Amine Bonds on Proteins through Aza-Michael Ligation
Freedy, A. M., Matos, M. J., Boutureira, O., Corzana, F., Guerreiro, A., Akkapeddi, P., Somovilla, V. J., Rodrigues, T., Nicholls, K., Xie, B., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b10702 · Cited by 104
When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
Tapia‐Galisteo, A., Compte, M., Álvarez‐Vallina, L., & Sanz, L. (2023) · Theranostics · doi:10.7150/thno.81494 · Cited by 105
A comprehensive review of the neonatal Fc receptor and its application in drug delivery
Martins, J. P., Kennedy, P. J., Santos, H. A., Barrias, C. C., & Sarmento, B. F. C. C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.007 · Cited by 106
Assessing developability early in the discovery process for novel biologics
Fernández‐Quintero, M. L., Ljungars, A., Waibl, F., Greiff, V., Andersen, J. T., Gjølberg, T. T., Jenkins, T. P., Voldborg, B. G. R., Grav, L. M., Kumar, S., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2171248 · Cited by 101
Self-citationA human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Grevys, A., Nilsen, J., Sand, K. M. K., Daba, M. B., Øynebråten, I., Bern, M., McAdam, M. B., Foss, S., Schlothauer, T., Michaelsen, T. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03061-x · Cited by 98
Self-citationAlbumin: An Emerging Opportunity in Drug Delivery
Rahimizadeh, P., Yang, S., & Lim, S. I. (2020) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-019-0512-9 · Cited by 87
Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
Kelly, J. M., Amor‐Coarasa, A., Nikolopoulou, A., Wüstemann, T., Barelli, P. J., Kim, D., Williams, C. M., Zheng, X., Bi, C., Hu, B. X., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188722 · Cited by 85
Azevedo, C., Nilsen, J., Grevys, A., Nunes, R., Andersen, J. T., & Sarmento, B. F. C. C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.005 · Cited by 89
Self-citationRoopenian, D. C., Low, B. E., Christianson, G. J., Proetzel, G., Sproule, T. J., & Wiles, M. V. (2015) · mAbs · doi:10.1080/19420862.2015.1008345 · Cited by 85
Schmidt, E. G. W., Hvam, M. L., Antunes, F., Cameron, J., Viuff, D., Andersen, B., Kristensen, N. N., & Howard, K. A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.794248 · Cited by 89
Self-citationAlbumin-based drug designs for pharmacokinetic modulation
Pilati, D., & Howard, K. A. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1801633 · Cited by 84
Dietary vs. pharmacological doses of zinc: A clinical review
Santos, H. O., Teixeira, F. J., & Schoenfeld, B. J. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.06.024 · Cited by 77
Human and mouse albumin bind their respective neonatal Fc receptors differently
Nilsen, J., Bern, M., Sand, K. M. K., Grevys, A., Dalhus, B., Sandlie, I., & Andersen, J. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-32817-0 · Cited by 77
Self-citationAn intact C-terminal end of albumin is required for its long half-life in humans
Nilsen, J., Trabjerg, E., Grevys, A., Azevedo, C., Brennan, S. O., Stensland, M., Wilson, J. J., Sand, K. M. K., Bern, M., Dalhus, B., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0903-7 · Cited by 82
Self-citationProtein Engineering Strategies for Improved Pharmacokinetics
Rondon, A., Mahri, S., Morales-Yánez, F., Dumoulin, M., & Rita Vanbever, A. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202101633 · Cited by 73
Bern, M., Nilsen, J., Ferrarese, M., Sand, K. M. K., Gjølberg, T. T., Lode, H. E., Davidson, R. J., Camire, R. M., Bækkevold, E. S., Foss, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0580 · Cited by 76
Self-citationAlbumin-hitchhiking: Fostering the pharmacokinetics and anticancer therapeutics
Famta, P., Shah, S., Jain, N., Srinivasarao, D. A., Murthy, A. N., Ahmed, T., Vambhurkar, G. B., Shahrukh, S., Singh, S. B., & Srivastava, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.034 · Cited by 68
Austin, R. J., Lemon, B. D., Aaron, W. H., Barath, M., Culp, P., DuBridge, R. B., Evnin, L. B., Jones, A. D., Panchal, A. P., Patnaik, P., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0061 · Cited by 65
Mandrup, O. A., Ong, S. C., Lykkemark, S., Dinesen, A., Rudnik‐Jansen, I., Dagnæs-Hansen, N. F., Andersen, J. T., Álvarez‐Vallina, L., & Howard, K. A. (2021) · Communications Biology · doi:10.1038/s42003-021-01790-2 · Cited by 68
Self-citationFusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics
Jacobs, S. A., Gibbs, A. C., Conk, M., Yi, F., Maguire, D., Kane, C. M., & O’Neil, K. T. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv040 · Cited by 65
Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Tan, H., Su, W., Zhang, W., Wang, P., Sattler, M., & Zou, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190206105232 · Cited by 62
Human serum albumin binders: A piggyback ride for long-acting therapeutics
Ullah, A., Shin, G., & Lim, S. I. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103738 · Cited by 60
Sand, K. M. K., Bern, M., Nilsen, J., Dalhus, B., Gunnarsen, K. S., Cameron, J., Grevys, A., Bunting, K. A., Sandlie, I., & Andersen, J. T. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.587675 · Cited by 59
Self-citationProtein Engineering: A New Frontier for Biological Therapeutics
Tobin, P. J., Richards, D., Callender, R., & Wilson, C. J. (2014) · Current Drug Metabolism · doi:10.2174/1389200216666141208151524 · Cited by 54
Mester, S., Evers, M., Meyer, S., Nilsen, J., Greiff, V., Sandlie, I., Leusen, J. H. W., & Andersen, J. T. (2021) · mAbs · doi:10.1080/19420862.2021.1893888 · Cited by 54
Self-citationMarotta, C., Giorgi, E., Binacchi, F., Cirri, D., Gabbiani, C., & Pratesi, A. (2023) · Inorganica Chimica Acta · doi:10.1016/j.ica.2023.121388 · Cited by 50
Bradford, H. F., Haljasmägi, L., Menon, M., McDonnell, T. C. R., Särekannu, K., Vanker, M., Peterson, P., Wincup, C., Abida, R., González, R. F., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100894 · Cited by 55
Matos, M. J., Labão‐Almeida, C., Sayers, C. T., Dada, O., Tacke, M., & Bernardes, G. J. L. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201800872 · Cited by 48
Viuff, D., Antunes, F., Evans, L. R., Cameron, J., Dyrnesli, H., Ravn, B. T., Stougaard, M., Thiam, K., Andersen, B., Kjærulff, S., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.019 · Cited by 47
Self-citationLarsen, M. T., Mandrup, O. A., Schelde, K. K., Luo, Y., Sørensen, K. D., Dagnæs‐Hansen, F., Cameron, J., Stougaard, M., Steiniche, T., & Howard, K. A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.004 · Cited by 44
Self-citationSchueffl, H. H., Theiner, S., Hermann, G., Mayr, J., Fronik, P., Groza, D., Schoonhoven, S., Galvez, L., Sommerfeld, N. S., Schintlmeister, A., et al. (2021) · Chemical Science · doi:10.1039/d1sc03311e · Cited by 43
Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
Castro, L. S., Lobo, G. S., Pereira, P., Freire, M. G., Neves, M. C., & Pedro, A. Q. (2021) · Vaccines · doi:10.3390/vaccines9040328 · Cited by 48
Tincu, C.-E., Andrițoiu, C. V., Popa, M., & Ochiuz, L. (2023) · Polymers · doi:10.3390/polym15193969 · Cited by 43
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
Davé, E., Adams, R., Zaccheo, O., Carrington, B., Compson, J. E., Dugdale, S., Airey, M., Malcolm, S., Hailu, H., Wild, G., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1210747 · Cited by 43
Brandl, F., Merten, H., Zimmermann, M., Béhé, M. P., Zangemeister‐Wittke, U., & Plückthun, A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.030 · Cited by 42
Richter, W. F., Christianson, G. J., Frances, N., Grimm, H. P., Proetzel, G., & Roopenian, D. C. (2018) · mAbs · doi:10.1080/19420862.2018.1458808 · Cited by 39
Albumin in patients with liver disease shows an altered conformation
Paar, M., Fengler, V. H., Rosenberg, D. J., Krebs, A., Stauber, R. E., Oettl, K., & Hammel, M. (2021) · Communications Biology · doi:10.1038/s42003-021-02269-w · Cited by 38
Albumin is a reliable drug-delivering molecule: Highlighting points in cancer therapy
Asrorov, A. M., Mukhamedov, N., Kayumov, M., Yashinov, A., Wali, A., Yili, A., Mirzaakhmedov, S. Y., & Huang, Y. (2024) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2024.100186 · Cited by 40
Larsen, M. T., Rawsthorne, H., Schelde, K. K., Dagnæs‐Hansen, F., Cameron, J., & Howard, K. A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.023 · Cited by 38
Self-citationSoltaninejad, H., Zare‐Zardini, H., Ordooei, M., Ghelmani, Y., Ghadiri‐Anari, A., Mojahedi, S., & Hamidieh, A. A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/2894722 · Cited by 37
Mullin, M. J., McClory, J., Haynes, W. A., Grace, J., Robertson, N. J., & Heeke, G. V. (2024) · mAbs · doi:10.1080/19420862.2024.2341443 · Cited by 36
Hatada, M., Tsugawa, W., Kamio, E., Loew, N., Klonoff, D. C., & Sode, K. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.08.005 · Cited by 35
Konč, J., Brown, L., Whiten, D. R., Zuo, Y., Ravn, P., Klenerman, D., & Bernardes, G. J. L. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109713 · Cited by 32
Ueno, T., Hirayama, S., Sugihara, M., & Miida, T. (2015) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563215574350 · Cited by 31
Kuhlmann, M., Hamming, J. B. R., Voldum, A., Τσακιρίδου, Γ., Larsen, M. T., Schmøkel, J. S., Sohn, E., Bieńk, K., Schaffert, D., Sørensen, E. S., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.10.004 · Cited by 32
Species Differences in Tryptophan Metabolism and Disposition
Badawy, A. A. ‐., & Guillemin, G. J. (2022) · International Journal of Tryptophan Research · doi:10.1177/11786469221122511 · Cited by 32
Caspersen, M. B., Kuhlmann, M., Nicholls, K., Saxton, M. J., Andersen, B., Bunting, K. A., Cameron, J., & Howard, K. A. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0038 · Cited by 29
Self-citationAnimal models for evaluation of albumin-based therapeutics
Nilsen, J., Sandlie, I., Roopenian, D. C., & Andersen, J. T. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2017.11.007 · Cited by 30
Self-citationFelip, E., Moreno, V., Morgensztern, D., Curigliano, G., Rutkowski, P. L., Trigo, J. M., Calvo, A., Kowalski, D. M., Cortinovis, D. L., Plummer, R., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04414-6 · Cited by 25
Vodret, S., Bortolussi, G., Schreuder, A. B., Jašprová, J., Vı́tek, L., Verkade, H. J., & Muro, A. F. (2015) · Scientific Reports · doi:10.1038/srep16203 · Cited by 26
Schelde, K. K., Nicholls, K., Dagnæs‐Hansen, F., Bunting, K. A., Rawsthorne, H., Andersen, B., Finnis, C. J. A., Williamson, M., Cameron, J., & Howard, K. A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005870 · Cited by 25
Self-citationSchmøkel, J. S., Voldum, A., Τσακιρίδου, Γ., Kuhlmann, M., Cameron, J., Sørensen, E. S., Wengel, J., & Howard, K. A. (2017) · Nanotechnology · doi:10.1088/1361-6528/aa6a9b · Cited by 26
Self-citationRoles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus
Wang, J. W., Wu, W. H., Huang, T., Wong, M., Kwak, K., Ozato, K., Hung, C., & Roden, R. B. S. (2018) · Journal of Virology · doi:10.1128/jvi.00572-18 · Cited by 25
Anthi, A. K., Kolderup, A., Vaage, E. B., Bern, M., Benjakul, S., Tjärnhage, E., Ruso‐Julve, F., Jensen, K.-R., Lode, H. E., Vaysburd, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59353-6 · Cited by 29
Self-citationIyengar, A. R. S., Gupta, S., Jawalekar, S. S., & Pande, A. H. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.257063 · Cited by 25
Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometry
Lee, J. J., Seraj, J., Yoshida, K., Mizuguchi, H., Strychor, S., Fiejdasz, J., Faulkner, T., Parise, R. A., Fawcett, P., Pollice, L., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2965-2 · Cited by 23
Azevedo, C., Pinto, S. F. T., Benjakul, S., Nilsen, J., Santos, H. A., Traverso, G., Andersen, J. T., & Sarmento, B. F. C. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.016 · Cited by 26
Self-citationPetersen, S. S., Kläning, E., Ebbesen, M. F., Andersen, B., Cameron, J., Sørensen, E. S., & Howard, K. A. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00605 · Cited by 24
Self-citationBukrinski, J. T., Sønderby, P., Antunes, F., Andersen, B., Schmidt, E. G. W., Peters, G. H. J., & Harris, P. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00492 · Cited by 22
Self-citationThe neonatal Fc receptor in mucosal immune regulation
Aaen, K. H., Anthi, A. K., Sandlie, I., Nilsen, J., Mester, S., & Andersen, J. T. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.13017 · Cited by 21
Self-citationFusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
Lombardi, S., Aaen, K. H., Nilsen, J., Ferrarese, M., Gjølberg, T. T., Bernardi, F., Pinotti, M., Andersen, J. T., & Branchini, A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17559 · Cited by 24
Self-citationBiology of Anti-TNF Agents in Immune-Mediated Inflammatory Diseases: Therapeutic Implications
Levy, R. A., Guzmán, R. A., Castañeda‐Hernández, G., Martinez-Vazquez, M. A., Damian, G. B., & Cara, C. (2016) · Immunotherapy · doi:10.2217/imt-2016-0067 · Cited by 21
Popova, T. V., Khan, H., Chubarov, A. S., Lisitskiy, V. A., Antonova, N. M., Евгеньевич, А. А., Shevelev, O. B., Zavjalov, E. L., Silnikov, V. N., Ahmad, S., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.061 · Cited by 21
FcRn as a Transporter for Nasal Delivery of Biologics: A Systematic Review
Fieux, M., Quellec, S. L., Bartier, S., Coste, A., Louis, B., Giroudon, C., Nourredine, M., & Béquignon, É. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126475 · Cited by 20
Nishiie-Yano, R., Hirayama, S., Tamura, M., Kanemochi, T., Ueno, T., Hirayama, A., Hori, A., Ai, T., Hirose, N., & Miida, T. (2019) · Biological Trace Element Research · doi:10.1007/s12011-019-01981-3 · Cited by 21
Sepp, A., Bergström, M., & Davies, M. L. (2020) · mAbs · doi:10.1080/19420862.2020.1832861 · Cited by 18
Yadav, S. P. S., Sandoval, R. M., Zhao, J., Huang, Y., Wang, E., Kumar, S., Campos, S. B., Rhodes, G. J., Mechref, Y. S., Molitoris, B. A., et al. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00428.2020 · Cited by 21
von der Wellen, J., Winterhalter, P., Siegert, M., Eyer, F., Thiermann, H., & John, H. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.04.025 · Cited by 21
Albumin: the next-generation Delivery Technology
Howard, K. A. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.124 · Cited by 20
Warnders, F.-J., Hooge, M. N. L., de Vries, E. G. E., & Kosterink, J. G. W. (2018) · Medicinal Research Reviews · doi:10.1002/med.21498 · Cited by 20
Yang, B., Kim, J. C., Seong, J., Tae, G., & Kwon, I. (2018) · Biomaterials Science · doi:10.1039/c8bm00456k · Cited by 18
Nilsen, J., Aaen, K. H., Benjakul, S., Ruso‐Julve, F., Greiner, T. U., Bejan, D., Stensland, M., Singh, S. K., Schlothauer, T., Sandlie, I., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08249-8 · Cited by 21
Self-citationHangiu, O., Compte, M., Dinesen, A., Navarro, R., Tapia‐Galisteo, A., Mandrup, O. A., Erce-Llamazares, A., Lázaro‐Gorines, R., Nehme-Álvarez, D., Domínguez-Alonso, C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104958 · Cited by 17
A Humanized Mouse Model to Study Human Albumin and Albumin Conjugates Pharmacokinetics
Low, B. E., & Wiles, M. V. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3661-8_7 · Cited by 18
Amatya, R., Park, T., Hwang, S., Yang, J. W., Lee, Y.-J., Cheong, H., Moon, C., Kwak, H. D., Min, K. A., & Shin, M. C. (2020) · Toxins · doi:10.3390/toxins12050313 · Cited by 16
Human arginase 1, a Jack of all trades?
Anakha, J., Kawathe, P. S., Datta, S., Jawalekar, S. S., Banerjee, U. C., & Pande, A. H. (2022) · 3 Biotech · doi:10.1007/s13205-022-03326-9 · Cited by 18
Mamedov, T., Gürbüzaslan, İ., Yuksel, D., Ilgın, M., Mammadova, G., Özkul, A., & Hasanova, G. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.742875 · Cited by 15
Metadata
- Authors
- Andersen, J. T., Dalhus, B., Viuff, D., Ravn, B. T., Gunnarsen, K. S., Plumridge, A., Bunting, K., Antunes, F., Williamson, R., Athwal, S., Allan, E., Evans, L., Bjørås, M., Kjærulff, S., Sleep, D., Sandlie, I., & Cameron, J.
- Affiliations
- University of Oslo (NO)
- Oslo University Hospital (NO)
- Novozymes (United Kingdom) (GB)
- Novozymes (Denmark) (DK)
- Corresponding author
- Andersen, Jan Terje
- Cameron, Jason
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 289
- Issue
- 19
- Pages
- 13492-13502
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC4036356
- OpenAlex
- W2088696708
- Cited by
- 167
- References
- 37
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 11 · 2023: 14 · 2022: 12 · 2021: 22 · 2020: 15 · 2019: 11 · 2018: 16 · 2017: 9 · 2016: 14 · 2015: 13 · 2014: 5
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- human serum albumin, neonatal Fc receptor, serum half-life, albumin variants, scFv, Macaca fascicularis, biopharmaceuticals
- MeSH terms
- Albumins, Animals, Female, Half-Life, Humans, Macaca fascicularis, Receptors, Fc, Recombinant Fusion Proteins, Histocompatibility Antigens Class I, Amino Acid Substitution, Mutation, Missense, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
